eClinical Tech News

Surrozen reported third-quarter 2025 results and a tightened focus on ophthalmology, advancing two preclinical retinal candidates, SZN-8141 and SZN-8143,...

Exicure reported third-quarter 2025 results that underscore a high-risk pivot. The company ended the quarter with $4.4 million in...

Eton Pharmaceuticals posted another step-change quarter, reporting Q3 2025 product sales of $22.5 million, up 129% year over year...

Sana Biotechnology is refocusing its pipeline around two programs: SC451, a hypoimmune, iPSC‑derived pancreatic islet cell therapy for type...

Camp4 Therapeutics has secured up to $100 million in private financing, initiated GLP toxicology studies for its SYNGAP1 program...

Rezolute set December 2025 as the topline Phase 3 results date for congenital hyperinsulinism and secured FDA alignment that...

Collegium Pharmaceutical posted a record quarter and raised its outlook. For Q3 2025, the company reported $209.4 million in...

Cognition Therapeutics secured $30 million in a registered direct offering. It reached alignment with the FDA on a potential...

Iovance Biotherapeutics posted third-quarter 2025 product revenue of about $68 million, up 13% sequentially, with U.S. sales of its...

VYNE Therapeutics has kicked off a strategic review while advancing a repeat 12-week non-clinical toxicology study for VYN202, its...